OP-6D - Discontinuation Rate of Tofacitinib Is Similar When Compared to TNF Inhibitors in Rheumatoid Arthritis Patients: Data from a Rheumatoid Arthritis Cohort
Location: OP-06
Biologics/Biosimilars
Tuesday, Aug 24th
3:30 PM - 4:45 PM US Eastern Time
SP02D - The Risk of Serious Infection in Rheumatoid Arthritis Patients Receiving Tocilizumab Compared with Tumor Necrosis Factor Inhibitors in Korea
Location: SP02
Biologics/Biosimilars
Tuesday, Aug 24th
3:30 PM - 4:45 PM US Eastern Time
SP03B - Colonoscopy Use After Treatment Initiation in US Commercially Insured Patients with Inflammatory Bowel Disease, 2013-2018
Location: SP03
Biologics/Biosimilars
Tuesday, Aug 24th
3:30 PM - 4:45 PM US Eastern Time
SP03E - What Happened to Rheumatoid Arthritis Patients Who Stopped Biologic or Targeted Synthetic Disease Modifying Antirheumatic Therapy?
Location: SP03
Biologics/Biosimilars
Tuesday, Aug 24th
3:30 PM - 4:45 PM US Eastern Time
SP03G - Outpatient Transfusions and Occurrence of Febrile Non-hemolytic Transfusion Reactions Among U.S. Medicare Beneficiaries, Ages 65 and Older, During 2011-2018: Utility of Real-world Data
Location: SP03
Biologics/Biosimilars
Tuesday, Aug 24th
6:45 PM - 7:45 PM US Eastern Time
L-3P - Risk of Major Cardiovascular Event in Jak Inhibitor Treated Patients: Analysis of a National Claim Database
